Also found in: Wikipedia.


n.1.(Old Pharmacy) A compound cordial, in the form of a confection, deriving its name from the kermes insect, its principal ingredient.
References in periodicals archive ?
agreed to sell its remaining 7,750,000 shares of Alkermes plc.
In March 2012, Elan sold 24,150,000 shares of Alkermes in a public offering.
M2 EQUITYBITES-September 19, 2011-Alkermes plc and Elan Corporation plc reports establishment of Dublin based Alkermes plc(C)2011 M2 COMMUNICATIONS http://www.
DUBLIN -- Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.
DUBLIN -- Alkermes plc (NASDAQ: ALKS) and Elan Corporation, plc (NYSE: ELN) ("Elan") today announced the completion of the merger between Alkermes, Inc.
NASDAQ: ALKS) today announced that Alkermes shareholders have approved the merger of Alkermes and Elan Drug Technologies ("EDT"), the profitable drug formulation and manufacturing business unit of Elan Corporation, plc (NYSE: ELN) ("Elan").
At the meeting, members of Alkermes' senior management and a guest speaker from Elan Drug Technologies (EDT) will provide an update on the merger of Alkermes and EDT, including the combined company's outlook, commercial products, pipeline candidates and financial expectations.
Transaction Immediately Accretive to Cash Earnings; Alkermes plc to be Immediately Profitable on a Cash Basis with Growing Revenues in Excess of $450 Million Annually --
Alkermes developed, manufactures and commercializes VIVITROL([R]) for alcohol dependence and manufactures RISPERDAL([R]) CONSTA([R])for schizophrenia and bipolar I disorder.
Alkermes is an exciting company and David leaves it in a strong position as we prepare for the approval of exenatide once weekly, complete the VIVITROL([R]) pivotal study to expand the label into the opioid dependence indication and expand our pipeline of innovative medicines," said Richard Pops.
Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Thursday, November 13, 2008.
NASDAQ: ALKS) announced that it has received a letter terminating the development and license agreement between Eli Lilly and Company (Lilly) and Alkermes dated April 1, 2001 thereby terminating the AIR([R]) Inhaled Insulin (AIR([R]) Insulin) program.